Transcend Capital Advisors LLC Has $273,000 Holdings in Kenvue Inc. $KVUE

Transcend Capital Advisors LLC trimmed its holdings in Kenvue Inc. (NYSE:KVUE) by 66.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,793 shares of the company’s stock after selling 33,962 shares during the period. Transcend Capital Advisors LLC’s holdings in Kenvue were worth $273,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in Kenvue by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 233,246,267 shares of the company’s stock valued at $4,881,844,000 after buying an additional 4,101,880 shares during the period. Geode Capital Management LLC raised its position in Kenvue by 1.2% in the second quarter. Geode Capital Management LLC now owns 49,001,887 shares of the company’s stock valued at $1,021,267,000 after purchasing an additional 604,953 shares during the last quarter. Independent Franchise Partners LLP raised its holdings in Kenvue by 233.4% in the 2nd quarter. Independent Franchise Partners LLP now owns 31,265,574 shares of the company’s stock valued at $654,388,000 after buying an additional 21,886,537 shares during the last quarter. American Century Companies Inc. raised its stake in shares of Kenvue by 38.6% during the second quarter. American Century Companies Inc. now owns 30,265,020 shares of the company’s stock valued at $633,447,000 after acquiring an additional 8,436,166 shares during the last quarter. Finally, Norges Bank bought a new position in Kenvue during the 2nd quarter worth $537,418,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $17.99 on Thursday. The firm has a market capitalization of $34.47 billion, a PE ratio of 23.99 and a beta of 0.59. The company has a 50-day moving average price of $17.20 and a two-hundred day moving average price of $17.93. Kenvue Inc. has a twelve month low of $14.02 and a twelve month high of $25.17. The company has a quick ratio of 0.69, a current ratio of 0.98 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last posted its earnings results on Monday, November 3rd. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. The business had revenue of $3.76 billion during the quarter, compared to analyst estimates of $3.83 billion. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The company’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.28 EPS. Equities analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 25th. Stockholders of record on Wednesday, February 11th will be given a dividend of $0.2075 per share. The ex-dividend date is Wednesday, February 11th. This represents a $0.83 annualized dividend and a dividend yield of 4.6%. Kenvue’s dividend payout ratio (DPR) is 110.67%.

Analyst Ratings Changes

A number of analysts have weighed in on KVUE shares. Edward Jones downgraded shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 3rd. JPMorgan Chase & Co. decreased their target price on Kenvue from $24.00 to $21.00 and set an “overweight” rating for the company in a research report on Friday, October 10th. Canaccord Genuity Group restated a “hold” rating and set a $15.00 price target (down previously from $26.00) on shares of Kenvue in a research note on Wednesday, October 29th. Citigroup cut their price target on Kenvue from $20.00 to $17.00 and set a “neutral” rating for the company in a research note on Thursday, October 9th. Finally, Bank of America reduced their target price on shares of Kenvue from $25.00 to $21.00 and set a “buy” rating for the company in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and thirteen have issued a Hold rating to the company. Based on data from MarketBeat, Kenvue has an average rating of “Hold” and a consensus target price of $19.90.

Insiders Place Their Bets

In other news, Director Jeffrey C. Smith acquired 3,200,000 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were bought at an average cost of $17.37 per share, with a total value of $55,584,000.00. Following the acquisition, the director owned 27,307,632 shares in the company, valued at approximately $474,333,567.84. This represents a 13.27% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.68% of the stock is owned by insiders.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.